Evidence map›Paper›PMID 41266472›Full record

ArticleScientific reports2025

Design, synthesis, and biological evaluation of novel 6-(4-aminopiperidin-1-yl)-substituted benzyl-3-methylpyrimidine-2,4(1H,3H)-dione derivatives as potential anticancer agents targeting thymidylate synthase.

Ladan Baziar, Elaheh Ataollahi, Zahra Rezaei, Yousif Abdulkadhim, Mohammad Reza Abdolahi, Alireza Poustforoosh, Somayeh Zare, Mina Emami, Maryam Moghtader Mansouri, Leila Emami and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ladan Baziar *Department of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Elaheh Ataollahi *Pharmaceutical Sciences Research Center, Faculty of pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Zahra RezaeiDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Yousif AbdulkadhimStudent Research Committee, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Mohammad Reza AbdolahiStudent Research Committee, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Alireza PoustforooshMedicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.
Somayeh ZareDepartment of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences, Hormozgan University of Medical Sciences, Hormozgan, Iran.
Mina EmamiPharmaceutical Sciences Research Center, Faculty of pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Maryam Moghtader MansouriDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran.
Leila EmamiPharmaceutical Sciences Research Center, Faculty of pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. emamil@sums.ac.ir.
Soghra KhabnadidehDepartment of Medicinal Chemistry, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran. khabns@sums.ac.ir.

Funding

Shiraz Transplant Research Center, Shiraz University of Medical Sciences 30102
6 · The paper itself

Abstract

This study was undertaken to identify novel thymidylate synthase inhibitors with improved efficacy and selectivity over existing chemotherapeutics. A series of novel 6-(4-aminopiperidin-1-yl)-substituted benzyl-3-methylpyrimidine-2,4(1 H,3 H)-dione derivatives were designed, synthesized, and evaluated as potential anticancer agents. Among these, compound 5 h exhibited the most potent cytotoxicity, with IC

Indexed as

Antineoplastic AgentsEnzyme InhibitorsPyrimidinesThymidylate SynthaseApoptosisCell Line, TumorCell ProliferationDrug DesignHumansMCF-7 CellsMolecular Docking SimulationMolecular Dynamics SimulationAntineoplastic AgentsEnzyme InhibitorsPyrimidinesThymidylate SynthaseApoptosisCell cycle arrestMolecular dynamicsPiperidinePyrimidineThymidylate synthase

Identifiers

PMID41266472
PMCPMC12635300

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.